{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004527","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.140271+00:00","generated_at":"2026-06-04T04:24:15.700206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ProMIS Neurosciences reports FY2023 net loss $13.2M, cash $12.6M; PMN310 Phase 1a data on track for mid-2024","bullets":["Cash and cash equivalents $12.6M at Dec 31, 2023, up from $5.9M; Q3 2023 PIPE raised $20.4M gross.","Net loss $13.2M for FY2023 vs $18.1M in FY2022; R&D expenses $7.9M vs $16.1M.","Phase 1a trial of PMN310 for Alzheimer's dosed Nov 2023; top-line safety/PK data expected mid-2024.","Lead vaccine candidate PMN400 selected for synucleinopathies (MSA, Parkinson's) in Jan 2024.","Neil Warma appointed interim CEO in Jan 2024; US/international patent allowances for AD antibody in Mar 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004527","json":"https://secwatch.observer/filing/0001558370-24-004527.json","markdown":"https://secwatch.observer/filing/0001558370-24-004527.md","text":"https://secwatch.observer/filing/0001558370-24-004527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024004527/0001558370-24-004527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024004527/pmn-20240401x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:24:15.700206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8921d004cc624416fba90db7db7d1ef3a9326352","claim":"ProMIS Neurosciences Inc. reported the fiscal year ended December 31, 2023 results: net income $13.2 million.","evidence_excerpt":"Net loss was $13.2 million for the full year ended December 31, 2023, compared to a net loss of $18.1 million for full year in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000155837024004527/0001558370-24-004527-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Net income","value":"$13.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}